Today's Stocks Driving Success For The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 21 points (0.1%) at 16,839 as of Wednesday, June 25, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,709 issues advancing vs. 1,282 declining with 166 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.2%. Top gainers within the industry include Bristol-Myers Squibb Company ( BMY), up 3.1%, Shire ( SHPG), up 3.1%, AbbVie ( ABBV), up 2.5%, Regeneron Pharmaceuticals ( REGN), up 2.5% and Eli Lilly and ( LLY), up 1.2%. On the negative front, top decliners within the industry include Grifols ( GRFS), down 2.1%, and Actavis ( ACT), down 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Johnson & Johnson ( JNJ) is one of the companies pushing the Drugs industry higher today. As of noon trading, Johnson & Johnson is up $0.90 (0.9%) to $105.49 on average volume. Thus far, 2.9 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 7.2 million shares. The stock has ranged in price between $104.23-$105.87 after having opened the day at $104.23 as compared to the previous trading day's close of $104.59.

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $297.8 billion and is part of the health care sector. Shares are up 14.2% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

IPOs That Should Be on Your Radar

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'

Johnson & Johnson Stock Sinks, Goldman Downgrades to 'Sell'

The Best Companies for Women